Please ensure Javascript is enabled for purposes of website accessibility

Silver Spring-based United Therapeutics’ drug fails test

United Therapeutics Corp. of Silver Spring, which develops pharmaceuticals to treat cardiovascular, infectious and oncological diseases, announced a setback in the Phase 3 clinical trial of an experimental lung-disorder drug.

The company said the 310-patient trial failed to show that the experimental treatment helped patients with pulmonary arterial hypertension walk farther, the study’s main goal.

The medicine is an oral version of the drug treprostinil, which is already approved to treat the life-threatening lung disorder by injected, intravenous and inhaled routes of administration.